Swiss Life Asset Management’s Elanco Animal Health ELAN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.08M Buy
44,054
+43
+0.1% +$994 ﹤0.01% 682
2026
Q1
$1.05M Buy
44,011
+8,520
+24% +$208K 0.01% 644
2025
Q4
$803K Buy
35,491
+12,702
+56% +$276K ﹤0.01% 679
2025
Q3
$459K Buy
22,789
+10,067
+79% +$169K ﹤0.01% 744
2025
Q2
$182K Buy
+12,722
New +$149K ﹤0.01% 832
2023
Q3
Sell
-136,888
Closed -$1.38M 627
2023
Q2
$1.38M Hold
136,888
0.02% 517
2023
Q1
$1.29M Buy
+136,888
New +$1.61M 0.02% 527
2022
Q3
Sell
-9,767
Closed -$192K 602
2022
Q2
$192K Buy
+9,767
New +$231K ﹤0.01% 587
2021
Q3
Sell
-300
Closed -$263K 557
2021
Q2
$263K Buy
+300
New +$9.89K ﹤0.01% 519
2020
Q2
Sell
-10,138
Closed -$227K 514
2020
Q1
$227K Buy
+10,138
New +$278K ﹤0.01% 478

Other funds holding ELAN

Swiss Life Asset Management's ELAN Position: Q2 2026 in Review

Swiss Life Asset Management increased its Elanco Animal Health (ELAN) stake by 0.1% in Q2 2026, buying an estimated $994 and bringing the position to 44,054 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #682.

Swiss Life Asset Management first reported a position in ELAN in Q1 2020 and has held it in 10 quarters since. The position peaked at $1.38M in Q2 2023. 409 funds tracked by Wall St. Rank hold ELAN as of Q2 2026.

  • Swiss Life Asset Management held 44,054 shares of Elanco Animal Health worth $1.08M as of Q2 2026.
  • Swiss Life Asset Management bought 43 Elanco Animal Health shares in Q2 2026, an estimated $994.
  • Elanco Animal Health made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #682 holding.
  • Swiss Life Asset Management first reported a position in Elanco Animal Health in Q1 2020 and has held it in 10 quarters since.
  • Swiss Life Asset Management's Elanco Animal Health position peaked at $1.38M in Q2 2023.
  • 409 funds tracked by Wall St. Rank held Elanco Animal Health as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.